Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up

All News TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Market Closed - Euronext Paris
Other stock markets
 11:35:09 2024-07-05 am EDT 		5-day change 1st Jan Change
0.1444 EUR +1.55% Intraday chart for TME Pharma N.V. -3.73% -37.22%
Jun. 27 TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board CI
Jun. 19 TME Pharma: in the red, a broker cuts its target CF

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TME Pharma Provides Results of Second Exercise of Warrants Z
BU
TME Pharma Announces Appointment of Lee Schalop to Supervisory Board and Approval of All Resolutions Submitted to the 2024 Annual General Meeting of Shareholders
BU
TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board
CI
TME Pharma: in the red, a broker cuts its target
CF
TME PHARMA : Invest Securities reduces its target
CF
TME PHARMA ANNOUNCES PUBLICATION IN NATURE COMMUNICATIONS OF BIOMARKER DATA FROM NOX-A12 GLORIA PHASE TRIAL IN GLIOBLASTOMA
AQ
TME Pharma Announces Results of Successful Capital Increase With €2.35 Million Raised
BU
TME Pharma Announces a Financing Guarantee Agreement and the Launch of Capital Increase of Minimum 2.2 Million Euros
BU
TME Pharma N : announces a financing guarantee agreement and the launch of capital increase of minimum 2.2 million euros
PU
TME Pharma Announces Publication in Nature Communications of Biomarker Data From NOX-A12 Gloria Phase 1/2 Trial in Glioblastoma
BU
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
BU
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
TME Pharma Publishes 2023 Financial Results and Provides Operating Update
BU
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER
AQ
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
BU
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
CI
TME Pharma: Fast Track designation in glioblastoma
CF
TME Pharma N : Inside Information / Other news releases
PU
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
BU
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALTME Stock
  4. News TME Pharma N.V.